Biogen (BIIB) Long-Term Investments (2009 - 2026)

Biogen (BIIB) has reported Long-Term Investments for 17 consecutive years, with $465.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments changed N/A year-over-year to $465.6 million; the TTM figure through Mar 2026 stood at $465.6 million (changed N/A YoY), while the FY2025 annual figure was $431.9 million, changed N/A from the prior year.
• Long-Term Investments came in at $465.6 million for Q1 2026 at Biogen, up from $431.9 million in the prior quarter.
• The five-year high for Long-Term Investments was $1.2 billion in Q2 2023, with the low at $100000.0 in Q3 2023.
• Average Long-Term Investments over 4 years is $750.5 million, with a median of $860.3 million recorded in 2022.
• Across the five-year window, Long-Term Investments grew 21.86% in 2022 and sank 99.99% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $705.7 million in 2022, then sank by 99.99% to $100000.0 in 2023, then jumped by 431800.0% to $431.9 million in 2025, then gained by 7.8% to $465.6 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $465.6 million, $431.9 million, and $100000.0 for Q1 2026, Q4 2025, and Q3 2023 respectively.